Free Trial
NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

Codexis logo
$2.72 +0.05 (+1.87%)
Closing price 04:00 PM Eastern
Extended Trading
$2.77 +0.05 (+1.84%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Codexis Stock (NASDAQ:CDXS)

Key Stats

Today's Range
$2.66
$2.79
50-Day Range
$2.29
$3.33
52-Week Range
$1.90
$6.08
Volume
678,839 shs
Average Volume
1.34 million shs
Market Capitalization
$245.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Moderate Buy

Company Overview

Codexis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

CDXS MarketRank™: 

Codexis scored higher than 77% of companies evaluated by MarketBeat, and ranked 269th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Codexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Codexis has received no research coverage in the past 90 days.

  • Read more about Codexis' stock forecast and price target.
  • Earnings Growth

    Earnings for Codexis are expected to grow in the coming year, from ($0.77) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Codexis is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Codexis is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Codexis has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Codexis' valuation and earnings.
  • Percentage of Shares Shorted

    6.85% of the float of Codexis has been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 2.28%, indicating that investor sentiment is improving.
  • Dividend Yield

    Codexis does not currently pay a dividend.

  • Dividend Growth

    Codexis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.85% of the float of Codexis has been sold short.
  • Short Interest Ratio / Days to Cover

    Codexis has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Codexis has recently decreased by 2.28%, indicating that investor sentiment is improving.
  • News Sentiment

    Codexis has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.02 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Codexis this week, compared to 3 articles on an average week.
  • Search Interest

    3 people have searched for CDXS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Codexis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.90% of the stock of Codexis is held by insiders.

  • Percentage Held by Institutions

    78.54% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Codexis' insider trading history.
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDXS Stock News Headlines

Codexis to Participate in Cantor Global Healthcare Conference
Codexis FY2025 EPS Estimate Reduced by Cantor Fitzgerald
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Codexis (NASDAQ:CDXS) Raised to "Hold" at Wall Street Zen
Codexis Inc. (CDXS) Stock Price Today - WSJ
Codexis: Q2 Earnings Snapshot
See More Headlines

CDXS Stock Analysis - Frequently Asked Questions

Codexis' stock was trading at $4.77 on January 1st, 2025. Since then, CDXS shares have decreased by 43.0% and is now trading at $2.72.

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Wednesday, August, 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $15.33 million during the quarter, compared to analysts' expectations of $14.18 million. Codexis had a negative trailing twelve-month return on equity of 105.83% and a negative net margin of 113.67%.
Read the conference call transcript
.

Top institutional shareholders of Codexis include Opaleye Management Inc. (15.21%), Aberdeen Group plc (5.07%), Nantahala Capital Management LLC (4.87%) and Telemark Asset Management LLC (4.83%). Insiders that own company stock include Opaleye Management Inc, John J Nicols, Byron L Dorgan, Sriram Ryali, Kevin Norrett and Margaret Nell Fitzgerald.
View institutional ownership trends
.

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Codexis investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Walt Disney (DIS) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/13/2025
Today
8/28/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDXS
CIK
1200375
Employees
250
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$11.00
Potential Upside/Downside
+304.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.28 million
Net Margins
-113.67%
Pretax Margin
-113.61%
Return on Equity
-105.83%
Return on Assets
-46.06%

Debt

Debt-to-Equity Ratio
0.71
Current Ratio
5.82
Quick Ratio
5.70

Sales & Book Value

Annual Sales
$59.35 million
Price / Sales
4.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.62 per share
Price / Book
4.39

Miscellaneous

Outstanding Shares
90,270,000
Free Float
88,552,000
Market Cap
$245.53 million
Optionable
Optionable
Beta
2.54
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CDXS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners